Humanigen is taking action on the novel coronavirus outbreak. Refer to this page for the latest educational resources and information on lenzilumab as a therapeutic for cytokine storm resulting from COVID-19 infection.

Follow us on Twitter

Learn how Lenzilumab™ may reduce serious or fatal outcomes in COVID-19 patients

Captions available (enable using video controls)
Available languages: English, Spanish (Español), Mandarin (國語), Cantonese (廣東話), Korean (한국어, 韓國語), French (Français), German (Deutsch), Italian (Italiano), Portuguese (Português)


Resources from Humanigen

Humanigen Investor Webinar: Results of the Initial Cohort of COVID-19 Patients Treated with Lenzilumab

June 16, 2020

Humanigen Reports Additional Analysis of Lenzilumab in Severe and Critical COVID-19 Patients

Read the Full Press Release

  • Article | Am J Respir Crit Care Med.

    Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 ARDS

  • Article | BioWorld

    Snowballing research preps avalanche to bury COVID-19

  • Preprint | medRxiv

    First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia

  • Interview | Proactive Investors

    Humanigen CEO Discusses Phase III Trial for Lenzilumab in  COVID-19 Patients

  • Article | The New York Times

    The Coronavirus Patients Betrayed by Their Own Immune Systems

  • Graphic | Reuters

    Ventilators: a bridge
    between life and death?

  • Research Letter | JAMA

    Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

  • Preprint | IHME

    Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator days and deaths

  • Opinion | Bloomberg

    Coronavirus: Why Surgeons Don't Want to Operate Right Now

  • Preprint | Cell Press

    Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

  • Preprint | bioRxiv

    GM-CSF and Cytokine Storm in Coronavirus

  • Research | JAMA Internal Medicine

    Acute Respiratory Distress Syndrome and Death in Coronavirus Patients

  • Article | BioWorld

    Humanigen preps lenzilumab for battle with COVID-19 symptom

  • Supplemental information | The Lancet

    Data on immunology and inflammation in COVID-19

  • Article | The Atlantic

    Why the Coronavirus Has Been So Successful

  • Review | American Society for Microbiology

    Into the Eye of the Cytokine Storm

  • Article | Evaluate

    Tiziana takes a deep breath and targets Covid-19

  • Preprint | medRxiv

    Lung bronchoalveolar immune cells in COVID-19

  • Journal | The Lancet

    Clinical features of coronavirus patients in Wuhan, China

  • Article | STAT

    Researchers rush to test vaccine in humans without animal testing

  • Article | MIT Technology Review

    A coronavirus vaccine will take at least 18 months—if it works at all

  • Humanigen Publication | blood

    GM-CSF inhibition reduces cytokine release syndrome

  • Article | National Geographic

    Here’s what coronavirus does to the body

  • Research | The Journal of Immunology

    GM-CSF but Not IL-17 Critical for Development of Interstitial Lung Disease in Mice

  • Review Article | Hindawi

    Pivotal Roles of GM-CSF in Autoimmunity and Inflammation

  • Article | Journal of Experimental Medicine

    GM-CSF / IL-6–dependent Th17 cell development and survival

  • Twitter

©2020 Humanigen, Inc.  All rights reserved